Purilax Fine® Lidocaine – Cross-Linked HA Dermal Filler | 1 × 1.1ml

Product Overview

Purilax Fine® Lidocaine is a professional cross-linked Hyaluronic Acid (HA) dermal filler developed for superficial facial wrinkle correction, fine-line reduction, delicate facial contouring and subtle soft tissue augmentation.

Formulated with 24mg/ml highly purified, non-animal stabilised cross-linked Hyaluronic Acid and 0.3% Lidocaine, Purilax Fine features a homogeneous monophasic gel designed to provide smooth aesthetic correction while maintaining natural-looking facial contours.

Positioned as a softer, fine-line-focused formulation, Purilax Fine is intended for professional treatments where subtle correction and refined enhancement are preferred over substantial structural volume restoration.

Its cohesive HA gel is designed to support smooth product distribution, mouldability and integration within appropriately selected tissues.

Potential professional treatment objectives include:

• Superficial facial wrinkle correction

• Fine-line improvement

• Perioral line correction

• Delicate facial contour refinement

• Selected lip border enhancement

• Subtle lip augmentation

• Improvement of selected facial lines

• Natural-looking facial rejuvenation

• Correction of minor soft tissue deficiencies

Purilax Fine contains 0.3% Lidocaine, a local anaesthetic incorporated to help reduce injection-related discomfort and improve patient comfort during treatment.

The cross-linked HA formulation provides immediate physical correction following appropriate placement. Hyaluronic Acid also has water-binding properties that contribute to moisture retention within the treated tissue.

Unlike non-cross-linked skin boosters, Purilax Fine is primarily a dermal filler designed for physical wrinkle correction and subtle soft tissue enhancement.

Purilax Fine® Lidocaine is intended strictly for use by appropriately qualified medical or aesthetic professionals trained in dermal filler procedures.

Pack Contents

Each pack contains:

• 1 × 1.1ml pre-filled syringe of Purilax Fine® Lidocaine

• Cross-Linked Hyaluronic Acid: 24mg/ml

• Lidocaine: 0.3%

• Sterile injection needle(s), as supplied by the manufacturer

• Sterile, sealed professional-use packaging

Volume per Syringe: 1.1ml

Total Product Volume: 1.1ml

HA Concentration: 24mg/ml

Calculated Total HA Content: 26.4mg per syringe

Always check the original product packaging, manufacturer labelling, supplied needle specifications and current Instructions for Use before administration.

Product Composition

Cross-Linked Hyaluronic Acid – 24mg/ml

Purilax Fine contains 24mg/ml cross-linked Hyaluronic Acid within a professional injectable dermal filler gel.

Hyaluronic Acid is naturally present within human tissues and plays an important role in hydration and extracellular matrix function.

Cross-linking improves the stability and persistence of HA compared with non-cross-linked formulations, allowing the gel to provide physical wrinkle correction and soft tissue support.

Within Purilax Fine, the HA formulation is designed to support:

• Fine-line correction

• Superficial wrinkle improvement

• Delicate soft tissue augmentation

• Subtle contour refinement

• Natural-looking correction

• Moisture retention within treated tissue

The product's intended characteristics make it relevant to treatments requiring refined correction rather than substantial facial projection.

Lidocaine – 0.3%

Purilax Fine contains 0.3% Lidocaine.

Lidocaine is a local anaesthetic incorporated into the formulation to help reduce injection-related discomfort and improve patient comfort.

Patients should be assessed for relevant allergies, hypersensitivities and contraindications before treatment.

Non-Animal Stabilised Hyaluronic Acid

The supplied product information describes Purilax Fine as containing highly purified, non-animal stabilised HA.

This is intended to provide a consistent injectable gel suitable for professional aesthetic correction.

Monophasic Cross-Linked HA Gel

Purilax Fine features a homogeneous monophasic gel structure.

Monophasic HA fillers are generally characterised by a cohesive gel phase rather than a suspension of discrete gel particles.

The supplied product information associates this structure with:

• Smooth delivery

• Mouldability

• Cohesion

• Tissue integration

• Refined correction

• Natural-looking results

The precise rheological characteristics would require confirmation from the manufacturer's technical documentation.

Monophasic Gel Technology

Purilax Fine is formulated using a monophasic cross-linked HA gel designed for delicate facial correction.

The gel structure is intended to provide balanced cohesion, flexibility and mouldability.

Homogeneous Gel Structure

The monophasic formulation provides a cohesive HA gel designed for smooth product distribution.

Mouldability

The gel is intended to accommodate refined contour correction within appropriately selected treatment areas.

Tissue Integration

The formulation is designed to integrate smoothly within the treated tissue following appropriate placement.

Flexibility

Its intended characteristics support subtle correction in facial regions where maintaining natural expression is important.

Cross-Linked HA Stability

The cross-linked HA matrix is designed to provide greater persistence than non-cross-linked Hyaluronic Acid formulations.

Controlled Product Delivery

The cohesive gel structure is intended to support controlled administration by appropriately trained professionals.

These characteristics position Purilax Fine as a fine-line-focused HA filler for subtle facial correction and enhancement.

Fine-Line & Superficial Wrinkle Correction

Purilax Fine is designed for professional treatment planning where correction of fine lines and superficial facial wrinkles is required.

Potential treatment objectives include:

• Softening superficial wrinkles

• Improving fine facial lines

• Restoring smoother-looking contours

• Refining selected facial areas

• Reducing the appearance of age-related fine lines

• Supporting natural-looking rejuvenation

The appropriate product should always be selected according to wrinkle depth, tissue characteristics, manufacturer-authorised indications and desired degree of correction.

Perioral Line Correction

Fine lines around the mouth may become more visible as a result of facial movement, changes in skin quality and age-related tissue changes.

Purilax Fine may be considered for selected perioral treatments where supported by the manufacturer's current Instructions for Use.

Potential objectives include:

• Softening appropriate perioral lines

• Improving the appearance of fine wrinkles

• Refining contours around the mouth

• Supporting natural-looking lower-face rejuvenation

The perioral region requires careful treatment planning because of its complex anatomy and frequent movement.

Lip Border Definition & Subtle Enhancement

The supplied product information identifies lip border definition and lip enhancement as potential applications.

Where clinically appropriate and supported by the manufacturer's current Instructions for Use, potential treatment objectives may include:

• Lip border refinement

• Subtle lip enhancement

• Improved lip definition

• Correction of selected asymmetry

• Restoration of minor volume deficiencies

• Natural-looking contour enhancement

Purilax Fine is positioned towards subtle correction rather than substantial lip projection or volume augmentation.

Product selection should reflect the patient's existing anatomy, tissue characteristics and desired outcome.

Delicate Facial Contour Refinement

Purilax Fine may be considered for selected areas requiring subtle soft tissue correction.

Potential objectives include:

• Refinement of delicate facial contours

• Improvement of superficial lines

• Correction of minor contour irregularities

• Natural-looking facial enhancement

• Improved appearance of selected facial wrinkles

The product should not be considered interchangeable with firmer structural fillers intended for deep facial projection.

Key Benefits

• Professional cross-linked HA dermal filler

• 1 × 1.1ml pre-filled syringe

• Contains 24mg/ml Hyaluronic Acid

• Contains 0.3% Lidocaine

• Highly purified, non-animal stabilised HA

• Homogeneous monophasic gel formulation

• Designed for superficial wrinkle correction

• Supports fine-line improvement

• Suitable for selected delicate facial treatments

• Supports subtle facial contour refinement

• May be considered for selected perioral lines

• Suitable for selected lip border treatments

• Supports natural-looking soft tissue enhancement

• Provides immediate physical correction

• Designed for smooth tissue integration

• Intended to provide good mouldability

• Cross-linked HA matrix supports gel stability

• Hyaluronic Acid contributes water-binding properties

• Lidocaine-containing formulation supports treatment comfort

• Designed for refined aesthetic correction

• Intended strictly for appropriately qualified professional use

Common Treatment Areas

The supplied product information identifies potential treatment areas including:

• Fine perioral lines

• Crow's feet

• Forehead lines

• Glabellar lines

• Lip border definition

• Selected lip enhancement

• Fine facial wrinkles

• Delicate facial contours

Treatment-area recommendations may vary according to the manufacturer's current Instructions for Use and the individual product supplied.

Important Anatomical Considerations

The glabella, forehead and periocular region are particularly sensitive areas for injectable dermal filler treatment because of their vascular anatomy.

Serious complications, including vascular occlusion, tissue necrosis and visual impairment or blindness, can occur following inappropriate intravascular administration.

The inclusion of an anatomical region in general product information does not automatically establish that it is an authorised indication.

Practitioners should only consider treatment areas explicitly supported by the manufacturer's current Instructions for Use and within their professional competence.

Treatment suitability must always be determined according to:

• Manufacturer-authorised indications

• Facial anatomy

• Vascular anatomy

• Wrinkle depth

• Tissue characteristics

• Previous aesthetic treatments

• Practitioner competence

• Individual treatment objectives

Purilax Fine vs Firmer Dermal Fillers

Purilax Fine is positioned towards fine-line correction and subtle facial enhancement.

Firmer structural fillers are generally selected for different treatment objectives.

Purilax Fine

Primarily positioned for:

• Superficial wrinkles

• Fine lines

• Delicate contour refinement

• Subtle lip enhancement

• Natural-looking facial correction

Primary focus: Refined, subtle aesthetic correction.

Firmer Structural Fillers

Primarily positioned for:

• Deeper wrinkle correction

• Facial volume restoration

• Structural tissue support

• Projection

• Cheek augmentation

• Chin enhancement

• Facial contour definition

Primary focus: Greater volume and structural support.

The appropriate product should be selected according to manufacturer-authorised indications, gel characteristics, patient anatomy and desired treatment outcomes.

Purilax Fine vs Skin Boosters

Purilax Fine should not be confused with a non-cross-linked HA skin booster.

HA Skin Boosters

These products primarily focus on:

• Hydration

• Moisture retention

• Skin texture

• Skin suppleness

• General skin-quality improvement

Purilax Fine

As a cross-linked HA dermal filler, Purilax Fine is designed primarily for:

• Physical fine-line correction

• Superficial wrinkle improvement

• Subtle soft tissue augmentation

• Delicate facial contour refinement

Although HA has water-binding properties, the primary purpose of Purilax Fine is physical aesthetic correction rather than general skin hydration.

Recommended Treatment Approach

Purilax Fine should only be administered following comprehensive professional assessment.

The supplied product information describes the following general approach:

• Initial Treatment: Single treatment session

• Product Volume: Individually determined

• Treatment Technique: Selected according to anatomy, practitioner training and manufacturer guidance

• Treatment Depth: Determined according to treatment area and current Instructions for Use

• Review: Approximately 2 weeks, where clinically indicated

• Additional Correction: May be considered following professional reassessment

• Maintenance: Approximately every 9–12 months, according to individual treatment response

These are supplied treatment recommendations rather than a universally validated protocol.

The manufacturer's current Instructions for Use should always take precedence.

Professional Treatment Considerations

Purilax Fine should only be administered by appropriately qualified and trained medical or aesthetic professionals with suitable competence in HA dermal filler procedures.

Treatment planning should include:

• Comprehensive patient consultation

• Full medical history

• Detailed facial assessment

• Assessment of wrinkle depth

• Assessment of tissue characteristics

• Evaluation of vascular anatomy

• Review of previous aesthetic procedures

• Assessment of contraindications

• Consideration of Lidocaine-related contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Treatment depth, product volume, administration technique and placement must always be determined according to individual anatomy and the manufacturer's current Instructions for Use.

Results & Treatment Outcomes

Purilax Fine provides immediate physical correction following appropriate professional placement.

Potential treatment outcomes include:

• Smoother-looking fine lines

• Improvement in selected superficial wrinkles

• Refined facial contours

• Improved lip border definition where appropriate

• Subtle soft tissue enhancement

• Natural-looking facial rejuvenation

Initial swelling may temporarily influence the appearance of the treated area.

The final aesthetic result becomes clearer as treatment-related swelling resolves.

Results & Longevity

The supplied product information describes results as commonly lasting approximately:

9–12 months

This should be considered an estimated range rather than a guaranteed duration.

Individual longevity may vary according to:

• Treatment area

• Product volume

• Treatment technique

• Treatment depth

• Patient metabolism

• Facial movement

• Patient age

• Lifestyle factors

• Tissue characteristics

• Individual biological response

Highly mobile treatment areas may demonstrate different persistence compared with less mobile regions.

Maintenance treatment may subsequently be considered following professional reassessment.

Storage & Handling

Purilax Fine should be stored and handled according to the manufacturer's current Instructions for Use and the information supplied with the original product.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow manufacturer-specified storage conditions.

• Protect from inappropriate environmental exposure.

• Inspect the syringe and outer packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Maintain appropriate aseptic handling procedures.

• Do not use if sterile packaging is damaged.

• Do not use if the syringe appears compromised.

• Do not use after the stated expiry date.

Each syringe should be handled according to the manufacturer's single-use instructions.

Important Information

Purilax Fine® Lidocaine is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Professional knowledge of the following is essential:

• Facial anatomy

• Vascular anatomy

• Dermal filler techniques

• Appropriate treatment planes

• Patient selection

• Aseptic practice

• Lidocaine-containing injectable products

• Complication prevention

• Recognition of vascular compromise

• Emergency management

• Dermal filler complication management

Patient Assessment

Treatment should only proceed following:

• Full patient consultation

• Comprehensive medical history

• Detailed facial assessment

• Examination of the proposed treatment area

• Review of previous aesthetic treatments

• Assessment of contraindications

• Assessment of known allergies and hypersensitivities

• Consideration of Lidocaine-related contraindications

• Discussion of expected outcomes

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Contraindications & Precautions

The supplied product information does not provide a complete manufacturer-defined contraindication list.

Treatment suitability should be carefully assessed where relevant factors include:

• Active infection or inflammation within the treatment area

• Known hypersensitivity to product components

• Known Lidocaine hypersensitivity

• Pregnancy or breastfeeding

• Uncontrolled medical conditions

• Other contraindications identified within the manufacturer's current Instructions for Use

This list is not exhaustive.

Potential Treatment Reactions

Temporary effects associated with injectable HA filler treatment may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Discomfort

• Localised firmness

• Temporary contour irregularity

The precise product-specific adverse-event profile should be confirmed from the manufacturer's current Instructions for Use.

Serious Dermal Filler Complications

Injectable dermal filler procedures can result in serious complications, including infection, inflammatory reactions and vascular complications.

Inadvertent intravascular administration can result in vascular occlusion and serious tissue injury.

Depending upon the anatomical area involved, complications may include tissue necrosis, visual impairment or blindness.

Practitioners must therefore have appropriate knowledge of facial vascular anatomy and be competent in recognising and managing filler-related complications.

Patients should receive appropriate written aftercare information and clear instructions regarding symptoms requiring urgent medical assessment.

Always consult the manufacturer's current Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, administration and potential adverse events.

For appropriately qualified professional use only.